Clinical Trial Update: Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating continuation versus de-escalation of bone-modifying agents in patients with bone metastases from breast cancer or castrat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Castration-resistant Prostate Cancer

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Breast Cancer, Castration-resistant Prostate Cancer | Phase 4 | Status: ACTIVE_NOT_RECRUITING